NANOM-FIM
Plasmonic Photothermal Therapy of Flow-Limiting Atherosclerotic Lesions With Silica-Gold Nanoparticles: a First-in-Man Study
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01270139/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 45–65 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 180 чел. во всех странах исследования.
- Центров в реестре: 3 в одном городе. Список — ниже на странице.
- Плановая дата окончания (08.2016) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 8 · невключение: 12
Критерии включения
- age 45-65 years old
- male and female
- single- or multi-vessel CAD with flow-limiting lesions
- no indications for coronary artery bypass surgery (CABG)
- stable angina with indications for percutaneous coronary interventions (PCI)
- NYHA (New York Heart Association) I-III functional class of heart failure (HF)
- treated hypertension (in supine position: systole >140 mm Hg, diastole >90 mm Hg)
- de novo treated.
Критерии невключения
- non-compliance,
- angiographic SYNTAX score ≥23
- history of myocardial infarction (MI), unstable angina, PCI or CABG, atrial fibrillation or other dysrhythmias, stroke
- presence of indications for CABG
- presence of contraindications for PCI or CABG
- NYHA IV functional class of HF
- diabetes mellitus (in case of fasting glucose >7.0 mM/L or random glucose >11.0 mM/L)
- untreated hypertension
- asthma
- known hypersensitivity or contraindications to anti-platelet drugs
- contrast sensitivity
- participation to any drug- or intervention-investigation during the previous 60 days
Источник: ClinicalTrials.gov, NCT01270139 · запись обновлена в реестре 17 марта 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 16
- Total Atheroma Volume — at 12-month follow-up
- MACE (Major Adverse Cardiovascular Events)-Free Survival — at 60 months follow-up
Цель исследования
The investigators hypothesize that the nanoburning is a very challenging technique to demolish and reverse the plaque especially in combination with stem cell technologies promising the functional restoration of the vessel wall.
The completed (in July 2012) interventional three arms (n=180) first-in-man trial (the NANOM-FIM trial) assessed (NCT01270139) the safety and feasibility of two delivery techniques for nanoparticles (NP), and plasmonic photothermal therapy (PPTT) of atherosclerotic lesions. Patients were assigned in a 1:1:1 ratio to receive either (1) nano-intervention with delivery of silica-gold NP in mini-surgery implanted bioengineered on-artery patch (n=60), or (2) nano-intervention with delivery of silica-gold iron-bearing NP with targeted micro-bubbles or stem cells in hands of magnetic navigation system (n=60) versus (3) stent implantation (n=60). The primary outcome was TAV at 12 months.
The observational prospective cohort analysis (an amendment to the protocol of August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively) of the long-term clinical outcomes at the intention-to-treat population of 180 patients with CAD and angiographic SYNTAX score ≤22 enrolled initially to NANOM-FIM trial will be performed at 5 years after the intervention. The primary outcome will be a MACE-free survival. The secondary outcomes will be MACE, cardiac death, TLR (target lesion revascularization) and TVR (target vessel revascularization). Imaging endpoints will be assessed pre-, post- procedure and at 12-month follow-up. Clinical endpoints will be analyzed at the baseline and at 12 and 60-month follow-up (the release of results is expected after October 2016). Parameters of nanotoxicity will be assessed. The independent adjudication analysis of the clinical outcomes is scheduled in 2017-2019.
The subset post-hoc analysis will be conducted at 1- and 5-year follow-up (by the Amendment of August 29th 2012). At the first subset, patients underwent stenting with XIENCE V stent proximal to the site of nano-intervention (n=13). Subjects in the second subset were undergone drug-coated balloon pre-dilation with further nano-technique (n=20). Lesions in patients of the third subset were not prepared for the nano-approach (n=147) (neither stenting nor balloon angioplasty). The analysis will be performed and results will be released after 2018 with the same clinical outcomes.
This project and related manuscripts were not prepared or funded in any part by a commercial organization. Nanoparticles and biomedical equipment were supplied free for the study by the non-profit Agiko and De Haar Research Task Force (Rotterdam-Amsterdam, the Netherlands). All rights of the authors are reserved. The access of the international academic or governmental organizations to the essential and primary data of the trial is restricted by the Russian governmental authorities due to the interest of the Russian Federal Security Service (FSB).
Где проходит
3 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01270139 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.